

September 5, 2007

Notice of Acquisition of the Company's Own Shares Through ToSTNeT-2

Japan, September 5, 2007 --- Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced the method of acquisition of its own shares in the market pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

Particulars

1. Method of the Acquisition

Shares will be purchased through ToSTNeT-2 (closing price transaction) of the Tokyo Stock Exchange at 8:45am on September 6, 2007 at the closing price of ¥ 5,170 on September 5, 2007 at the First Section of the Tokyo Stock Exchange. (The transaction will neither be executed by other trading systems nor at another trading time.) The purchase order will be executed within the trading time concerned.

2. Contents of Acquisition

(1) Class of shares to be acquired: Common stock of the Company

(2) Total number of shares to be acquired: 6.5 million shares

*1 Number of shares concerned will not be changed. A part or all of shares may not be purchased due to market conditions.

*2 The purchase will be executed by the selling order equivalent to the number of shares planned to be acquired.

3. Announcement of Acquisition

Result of acquisition will be announced after the completion of acquisition at 8:45am on September 6, 2007.

(Reference 1)

Resolution of the Board of Directors on August 28, 2007

- Reasons for acquisition of its own shares: In order to improve capital efficiency and enhance return to shareholders
- Class of shares to be acquired: Common stock of the Company
- Number of shares to be acquired: 8.3 million shares (maximum)
(equivalent to 1.60% of a total of issued shares)
- Aggregate amount of acquisition cost: ¥ 45 billion (maximum)
- Period of acquisition: From August 29, 2007 to September 20, 2007

(Reference 2)

Cumulative total of the its own shares after Resolution of the Board of Directors on August 28, 2007

1. Total number of shares purchased: 936,400shares
2. Total value of purchase: ¥ 4,927,656,000

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com